The adaptative tumor response to BRAF-targeted drugs that eventually leads to the onset of resistance includes increased expression of receptor protein kinases and their cytokine ligands through autocrine tumor cell production, paracrine contribution by the tumor microenvironment or systemic production [3–6]. This evidence concerns the gene BRAF and neoplasm.